Close Menu

NEW YORK — French diagnostics firm Theradiag said on Monday that it has received CE marks for four of its i-Tracker biotherapy monitoring test kits.

The newly CE-marked kits include i-Tracker Vedolizumab, i-Tracker Anti-Vedolizumab, i-Tracker Ustekinumab, and i-Tracker Anti-Ustekinumab, which are used to monitor the levels of drugs used to treat chronic gastrointestinal inflammatory conditions including Crohn's disease and ulcerative colitis.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.